Health TrialsbyHealthPanel

miRNA in Chronic Kidney Diseases

ConditionChronic Kidney Diseases
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-69
SponsorJosip Juraj Strossmayer University of Osijek

About this trial

Oxidative stress and endoplasmic reticulum (ER) stress play a key role in tubular damage in both acute kidney injury and chronic kidney disease (CKD). Oxidative stress in the kidneys promotes renal vascular remodeling and increases preglomerular resistance. These are key elements in hypertension, acute and chronic kidney injury, as well as diabetic nephropathy. Chronic renal hypoxia is highlighted as the final common pathway to end-stage renal disease (ESRD). MicroRNA molecules (miRNA) also play an important role in these processes. MicroRNAs (miRNAs) are regulators of gene expression and play a role in the progression of renal ischemia-reperfusion injury. Although the pathophysiological contribution of microRNAs (miRNAs) to kidney damage has also been highlighted, the effect of miRNAs on kidney damage under conditions of oxidative and ER stress remains understudied.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

healthy normotensive adults (eGFR CKD-EPI >90 mL/min/1.73 m2, BP <140/90 mmHg)

hypertensive adults (eGFR CKD-EPI >90 mL/min/1.73 m2, BP >140/90 mmHg)

patients with chronic kidney disease stage 3-5 (eGFR CKD-EPI< 60 mL/min/1.73 m2)

Disqualifiers

cardiovascular diseases, but hypertension

diabetes

cerebrovascular diseases

peripheral artery disease

Trial population

Patients with CKD and healthy controls, i.e. patients with hypertension without kidney damage (eGFR CKD-EPI \> 90 mL/min/1.73 m2). Subjects and controls will be age- and gender-matched. Inclusion criteria for patients with CKD: the study will include patients having chronic kidney disease of the 3rd - 5th degree (eGFR CKD-EPI\< 60 mL/min/1.73 m2).

Trial design

Design model

Case-crossover

Time perspective

Cross-sectional

Treatments tested in this trial

Not listed

Trial groups

90 Participants
are grouped into 3 trial groups
Group A: Chronic kidney disease group
Group B: Healthy controls
Group C: Hypertensive Group

Trial outcomes

Primary outcomes

1

Systemic microvascular function

Skin microvascular reactivity assessed by Laser Doppler flowmetry (post-occlusive reactive hyperemia, iontophoresis of acetylcholine and sodium nitroprusside) - measured in perfusion units (PU)

Time frame
Day 1
2

Serum level of antixidant enzymesprotein concentration of SOD, CAT and glutathione-peroxidase

Serum protein concentration of superoxide disimutase (SOD), catalase (CAT) and glutathione-peroxidase (GPx).

Time frame
Day 1
3

Detecton of miRNA of interest

The database for miRNA will be searched, and the miRNA of interest will be selected, determined and detected.

Time frame
Day 1

Secondary outcomes

1

Body fluid compartments

Total body water (L), extracellular water (L), intracellular water (L) and plasma fluid volume (L) will be assessed using non-invasive bioimpedance analysis (BIA).

Time frame
at one time point

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Josip Juraj Strossmayer University of Osijek

Lead sponsor

University Hospital Center Osijek

Collaborator

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: